Talcum powder cancer claims target J&J’s new consumer carve-out
Johnson & Johnson’s newly formed consumer business has been targeted by claims that its talcum powder can cause cancer, days before it attempts to complete the largest US initial public offering in almost 18 months.
Kenvue, which started its IPO roadshow this week, has been named in at least seven talc lawsuits filed since the start of April, according to regulatory filings and people familiar with the matter.
Les Funtleyder, a healthcare portfolio manager at E Squared Capital Management, said the litigation risk posed by the extension of talc claims to Kenvue could deter some investors from investing in the J&J carve-out.
This story originally appeared on: Financial Times - Author:Jamie Smyth
